Recipharm starts negotiations with LIDDS on large-scale manufacture of Liproca Depot
Potential in LIDDS’ technology platform for development of new treatments for diseases where local administration is desirable
Recipharm has commenced negotiations with Swedish pharmaceutical company LIDDS regarding collaboration on the manufacture of Liproca Depot, a potential treatment for prostate cancer, ahead of continued clinical development and a possible market launch in the future.
In a joint letter of intent the two companies have outlined their intention to collaborate on scale-up, manufacture and quality assurance of LIDDS’ pharmaceutical products.
The collaboration will initially focus on Liproca Depot, currently in Phase II clinical trials, but it may also include other products based on LIDDS’ drug-delivery technology that releases drugs locally, close to the tumour, so as to reduce the side effects and the number of doses.
The letter of intent follows a feasibility study performed by Recipharm, the results of which confirmed the possibility of developing a process for manufacture that ensures a high-quality end product.
Maria Lundberg, General Manager Recipharm Pharmaceutical Development, said: 'There is great potential in LIDDS’ technology platform for development of new treatments for diseases where local administration is desirable. We look forward to contributing with our technical expertise in the field of manufacture, so that cancer patients can in future be offered treatments associated with fewer side effects.'
